Elsevier

Journal of Thoracic Oncology

Volume 13, Issue 9, September 2018, Pages e185-e186
Journal of Thoracic Oncology

Letter to the Editor
Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

https://doi.org/10.1016/j.jtho.2018.04.029Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Disclosure: Dr. Cooper is an advisory board member and has received honoraria for lectures from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc. The remaining authors declare no conflict of interest.